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Mechanisms underlying progression of nonalcoholic fatty liver disease (NAFLD) are still incompletely characterized. Hypoxia
and hypoxia-inducible factors (HIFs) have been implicated in the pathogenesis of chronic liver diseases, but the actual role of
HIF-2a in the evolution of NAFLD has never been investigated in detail. In this study, we show that HIF-2a is selectively
overexpressed in the cytosol and the nuclei of hepatocytes in a very high percentage (>90%) of liver biopsies from a cohort of
NAFLD patients at different stages of the disease evolution. Similar features were also observed in mice with steatohepatitis
induced by feeding a methionine/choline-deficient diet. Experiments performed in mice carrying hepatocyte-specific deletion
of HIF-2a and related control littermates fed either a choline-deficient L-amino acid–defined or a methionine/choline-defi-
cient diet showed that HIF-2a deletion ameliorated the evolution of NAFLD by decreasing parenchymal injury, fatty liver,
lobular inflammation, and the development of liver fibrosis. The improvement in NAFLD progression in HIF-2a-deficient
mice was related to a selective down-regulation in the hepatocyte production of histidine-rich glycoprotein (HRGP), recently
proposed to sustain macrophage M1 polarization. In vitro experiments confirmed that the up-regulation of hepatocyte
HRGP expression was hypoxia-dependent and HIF-2a-dependent. Finally, analyses performed on specimens from NAFLD
patients indicated that HRGP was overexpressed in all patients showing hepatocyte nuclear staining for HIF-2a and revealed
a significant positive correlation between HIF-2a and HRGP liver transcript levels in these patients. Conclusions: These
results indicate that hepatocyte HIF-2a activation is a key feature in both human and experimental NAFLD and significantly
contributes to the disease progression through the up-regulation of HRGP production. (HEPATOLOGY 2018;67:2196-2214).
Nonalcoholic fatty liver disease (NAFLD),regarded as the hepatic manifestation of themetabolic syndrome, is becoming the most
frequent chronic liver disease (CLD) worldwide, with
a prevalence of up to 20%-30% in the general popula-
tion and even higher among obese individuals and/or
patients affected by type II diabetes mellitus.(1-6)
NAFLD can evolve (20%-30% of patients) into
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nonalcoholic steatohepatitis (NASH), characterized by
hepatocyte injury and lobular inflammation that, in
turn, can progress to fibrosis, cirrhosis, and hepatocel-
lular carcinoma; but at present mechanisms underlying
NAFLD progression are still incompletely character-
ized, and no validated therapy is available.(1,4-7)
Literature data suggest that hepatic hypoxia can
have a role in CLD progression and hepatocellular car-
cinoma development by sustaining both angiogenesis
and fibrogenesis as well as, possibly, inflammatory
response and autophagy, with hepatic myofibroblasts
being able to both respond to hypoxia and to act in
proangiogenic way.(8-11) The cellular response to hyp-
oxia is mainly operated by hypoxia-inducible factors
(HIFs), evolutionarily conserved heterodimeric tran-
scriptional factors consisting of an oxygen-sensitive a-
subunit (HIF-1a or HIF-2a) and a stable, constitu-
tively expressed b-subunit (HIF-1b).(12-14) So far, data
concerning the role of hypoxia and HIFs in NAFLD
are quite limited,(10) but morphological evidence indi-
cates that liver hypoxia develops in parallel with
NAFLD-mediated steatosis, particularly in perivenous
areas, similarly to what has been described for ethanol-
induced fatty liver.(15,16) Nonetheless, HIFs can be
regulated also by oxygen-independent mechanisms
such as mitochondrial dysfunction, reactive oxygen
species generation, and endoplasmic reticulum
stress.(8-14) In their turn, HIF-1a and HIF-2a can
modulate the cellular adaptive responses to hypoxia by
up-regulating either common or, more often, distinct
and nonoverlapping transcriptional programs. For
instance, HIF-1a promotes glucose consumption and
glycolysis, while lipid storage is mainly regulated by
HIF-2a.(12-14) These actions on cell metabolism are
potentially relevant for the pathogenesis of NAFLD
because hypoxic conditions have been reported to
stimulate lipid storage and inhibit lipid catabolism
through b-oxidation.(10,12,13,17) Although both HIF-
1a and HIF-2a affect lipid metabolism, experimental
studies indicate that HIF-2a activation leads to fatty
liver by both up-regulating genes involved in fatty acid
synthesis/uptake and lipid storage and down-
regulating those involved in fatty acid catabolism.(18,19)
HIF-2a activation has also been related to an early
increase in the transcription of proinflammatory cyto-
kines and of genes involved in fibrogenesis.(19) How-
ever, these data have been obtained in mice carrying
multiple genetic manipulations in the absence of liver
injury(18,19) or in the frame of a short protocol (2
weeks) of ethanol administration using the Lieber-De
Carli liquid diet, all conditions that do not reproduce
the conditions occurring in NAFLD.(19) At present,
relevant human data about the role of HIF-2a in fatty
liver development and NAFLD progression are lacking.
On the other hand, despite the fact that HIF-1a
appears to sustain fibrogenesis in the bile duct ligation
experimental model of CLD,(20) other studies designed
to specifically target hepatocyte HIF-1a in experimental
models of alcohol-related or NAFLD-related steatosis
and progression have led to conflicting results.(21-24)
In this study, the analysis of liver biopsies from a
cohort of NAFLD patients and the induction of
experimental NAFLD with two different dietary pro-
tocols in mice carrying hepatocyte-specific deletion of
HIF-2a provide evidence indicating that HIF-2a plays
a critical role in NAFLD progression by up-regulating
hepatocyte expression of histidine-rich glycoprotein
(HRGP).
Materials and Methods
HUMAN SUBJECTS
The study on NAFLD patients was approved by
the ethics committee of the Azienda Ospedaliera
Universitaria Citta della Salute (Turin, Italy). For this
study we analyzed liver biopsies from NAFLD patients
(n 5 27) ranging from early disease (stage F0-F1) to
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more advanced conditions of fibrosis (stage F2-F3) or
cirrhosis (F4) and referring to the Division of Gastro-
Hepatology of the University of Turin. All samples
were collected at the time of first diagnosis. Patients
were characterized by anthropometric, clinical, and
biochemical data; and liver biopsies were evaluated for
the severity of steatohepatitis and fibrosis according to
Kleiner et al.(25) All subjects gave informed consent to
the analysis, and the study protocol, which conformed
to the ethical guidelines of the 1975 Declaration of
Helsinki, was planned according to the guidelines of
the local ethics committee. The clinical and biochemi-
cal features of the patients are reported in Supporting
Table S1. Control human liver tissue (n 5 5), as
defined for normal histological structures in hematoxy-
lin and eosin sections and the absence of inflammation
in the portal tract and parenchyma, was obtained from
diagnostic biopsies or from resection samples taken at
a distance of more than 5 cm from the border of liver
metastasis of colon carcinoma.
ANIMAL EXPERIMENTATION
Mice carrying a hepatocyte-specific deletion of
HIF-2a (hHIF-2a–/–) were obtained by breeding
HIF-2afl/fl C57BL/6 mice with mice on the same
genetic background expressing Cre-recombinase under
the control of the albumin promoter (Alb/Cre1/1
mice; Jackson Laboratories, Bar Harbor, ME). Eight-
week-old male hHIF-2a–/– mice and related control
sibling littermates not carrying the HIF-2a deletion
were fed either a methionine/choline deficient (MCD)
diet for 4 or 8 weeks or a choline-deficient L-amino
acid–defined (CDAA) diet (Laboratorio Dottori
Piccioni, Gessate, Italy) for 12 and 24 weeks.(26,27)
Control littermates received the corresponding methi-
onine/choline-sufficient or the choline-sufficient
L-amino acid–defined (CSAA) diet. In preliminary
experiments 8-week-old normal C57BL/6 mice were
fed the MCD diet or the methionine/choline-suffi-
cient control diet for 4 and 8 weeks. The experiments
complied with national ethical guidelines for animal
experimentation, and the experimental protocols were
approved by the Italian Ministry of Health.
BIOCHEMICAL ANALYSES
Plasma alanine aminotransferase (ALT) and liver
triglycerides were determined by spectrometric kits
supplied by Radim S.p.A. (Pomezia, Italy) and Sigma
Diagnostics (Milan, Italy), respectively. Circulating
interleukin 12 (IL-12) was evaluated by commercial
enzyme-linked immunosorbent assay kits supplied by
Peprotech (Milan, Italy).
IMMUNOHISTOCHEMISTRY,
SIRIUS RED STAINING, AND
HISTOMORPHOMETRIC
ANALYSIS
Immunohistochemistry (IHC),(28,29) picro-sirius red
staining, and histomorphometric analysis(30,31) were
performed on paraffin-embedded human liver biopsies
and/or murine liver specimens as reported. More
details are in the Supporting Information.
QUANTITATIVE REAL-TIME PCR
RNA extraction, complementary DNA synthesis,
and quantitative real-time PCRs were performed on
human and murine liver specimens as described.(28-30)
mRNA levels were measured by quantitative real-time
PCR, using the SYBR green method as described.(28-
30) More details and oligonucleotide sequences of pri-
mers used for quantitative real-time PCR are available
in the Supporting Information. The murine transcripts
for tumour necrosis factor-a (TNFa), cluster of differ-
entiation 11b (CD11b), IL-12p40, C-C-motif che-
mokine ligand 2 (CCL2), C-X-C-motif chemokine
ligand 10, HRGP, and b-actin liver RNA were retro-
transcribed with the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems Italia, Monza,
Italy). Quantitative real-time PCR for these transcripts
was performed in a Techne TC-312 thermacycler
(TecneInc, Burlington, NJ) using TaqMan Gene
Expression Master Mix and TaqMan Gene Expres-
sion probes for indicated murine genes (Applied Bio-
systems Italia) as described.(26,31) Human sample
analysis was performed using SsoFast EvaGreen
Supermix (Bio-Rad, Hercules, CA) following the
manufacturer’s instructions.
INTRAHEPATIC
MONONUCLEATED CELL
ISOLATION AND FLOW-
CYTOMETRIC ANALYSIS
Hepatic mononucleated cells were isolated from the
livers of naive and CDAA–fed mice and purified on a
density gradient (Lympholyte-M; Cedarlane Labora-
toires Ltd., Burlington, Canada) as described.(31) Cells
were washed with Hank’s medium and incubated for
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30 min with decomplemented mouse serum to block
unspecific immunoglobulin binding. The cells were
then stained with fluorochrome-conjugated antibodies
for CD45, CD11b, Ly6C (eBiosciences, San Diego,
CA), and F4-80 (Invitrogen, Abingdon, UK) and ana-
lyzed with a Attune NxT acoustic focusing cytometer
(Thermo Fischer Scientific, Waltham, MA) following
prior gating for CD45 and the absence of cell aggre-
gates. Intracellular staining for IL-12 was performed
using a specific fluorochrome-conjugated antibody
(eBiosciences).
IN VITRO EXPERIMENTS AND
WESTERN BLOT ANALYSIS
In vitro experiments in this study were performed in
normal HepG2 cells (American Type Culture Collec-
tion) as well as in cells stably transfected in order to
overexpress HIF-2a in either normoxic or hypoxic
conditions, as reported.(28) Western blot analysis was
performed on total cell or tissue lysates as
described.(28,30) More details on in vitro studies and
western blot analysis are available in the Supporting
Information.
DATA ANALYSIS AND
STATISTICAL CALCULATIONS
Statistical analyses were performed by SPSS sta-
tistical software (SPSS Inc., Chicago, IL) using
one-way analysis of variance with Tukey’s correc-
tion for multiple comparisons or the Kruskal-Wallis
test for nonparametric values. Significance was
taken at the 5% level. Normality distribution was
preliminarily assessed by the Kolmogorov-Smirnov
algorithm.
Results
HIF-2a IS OVEREXPRESSED IN
HUMAN AND MURINE
HEPATOCYTES IN NAFLD-
RELATED LIVER SPECIMENS
IHC analysis of liver biopsies from a cohort of well-
characterized NAFLD patients (n 5 27, see Support-
ing Table S1 for patient characterization) at different
stages of the disease evolution showed an evident
increase of HIF-2a immune-staining compared to
undamaged liver samples (n 5 5) from patients
undergoing resection for hepatic metastasis of colon
carcinoma. In the majority of NAFLD patients (25
out of 27, 92%) HIF-2a positivity was detectable
almost exclusively in hepatocytes (Fig. 1A,B) and
involved both the cytoplasm and the nuclei, although
the number of positive nuclei varied within patients
and in different areas of the same biopsy (Fig. 1A).
The nuclei of nonparenchymal cells, mainly inflamma-
tory cells or myofibroblast-like cells in fibrotic septa,
were essentially negative for HIF-2a. Occasionally,
HIF-2a staining was observed in portal/periportal
cholangiocytes, particularly in subjects with advanced
fibrosis. Semiquantitative assessment of HIF-2a-
positive hepatocyte nuclei confirmed a significant
increase among NAFLD patients irrespective of the
stage of the disease (Fig. 1B). These findings were
reproduced in a rodent model of NAFLD-related liver
fibrosis based on mice fed the MCD diet up to 8 weeks
(Supporting Fig. S1A,B). In fact, while in control
mice HIF-2a staining was only detected in the cyto-
plasm of hepatocytes closely surrounding centrilobular
veins (Supporting Fig. S1A), extensive HIF-2a posi-
tivity was evident in liver sections from mice receiving
the MCD diet (Supporting Fig. S1B). In these ani-
mals quantitative real-time PCR analyses confirmed
that both HIF-2a as well HIF-1a transcripts were up-
regulated in mice with NAFLD, but only those of
HIF-2a paralleled the disease progression (Supporting
Fig. S1C-F).
HEPATOCYTE-SPECIFIC
DELETION OF HIF-2a IMPROVES
NAFLD-ASSOCIATED LIVER
INJURY, STEATOSIS,
INFLAMMATORY RESPONSE,
AND FIBROSIS
Based on previous data, we evaluated whether HIF-
2a deletion in hepatocytes might modify NAFLD evo-
lution. To this aim, progressive NAFLD was induced
in hHIF-2a–/– mice as well as related control litter-
mates by two dietary protocols using the MCD diet,
administered for 4 and 8 weeks, and the CDAA diet,
administered for 12 and 24 weeks. In preliminary
experiments, we first checked for effective HIF-2a
depletion in the livers of hHIF-2a–/– mice receiving
the MCD diet. Quantitative real-time PCR analysis
revealed a very significant down-regulation of
liver HIF-2a transcripts in hHIF-2a–/– mice compared
to control littermates (Supporting Fig. S2A-C),
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FIG. 1. Expression of HIF-2a in human liver disease. IHC analysis of HIF-2a in paraffin-embedded human liver specimens from
NAFLD patients (n 5 27) with different degrees of liver fibrosis (F0-F4) (A). “Control liver” refers to surgical resections for hepatic
metastasis of colon carcinoma (magnifications 320, 340, 3100). HIF-2a expression was semiquantitatively scored blinded, by a
pathologist. P < 0.05 (Mann-Whitney’s U test) (B).
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FIG. 2. Liver injury and inflammatory markers in hHIF2a–/– and control mice with NAFLD induced by feeding the MCD diet.
hHIF2a–/– and wild-type littermates were fed the MCD diet for 4 weeks, and the following parameters were evaluated: (A-C) paren-
chymal injury and liver steatosis, as evaluated by measuring (A) serum levels of ALT or (B) hepatic triglyceride content or, morpho-
logically, by hematoxylin/eosin staining (magnification 310) (C). (D) Liver expression of inflammatory markers TNF-a, CD11b, and
CCL2, as evaluated by quantitative real-time PCR. mRNA values are expressed as fold increase over control values after normalization
to the b-actin gene expression and are means 6 SD of six to eight animals per group. Boxes include the values within the 25th and
75th percentiles, while horizontal bars represent the medians. The extremities of the vertical bars (10th-90th percentile) comprise 80%
of the values. Statistical differences were assessed by one-way analysis of variance test with Tukey’s correction for multiple compari-
sons. Abbreviation: LM, littermate.
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whereas HIF-1a and vascular-endothelial growth
factor transcript levels were not affected. HIF-2a
deletion was also confirmed at the protein level
by western blotting of total liver proteins (Supporting
Fig. S2D).
Interestingly, in hHIF-2a–/– mice receiving the
MCD diet for 4 weeks the severity of steatohepatitis as
evaluated by histology, ALT release, and hepatic tri-
glyceride accumulation was significantly lower than in
HIF-2a-sufficient animals (Fig. 2A-C). The extent of
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FIG. 3. Liver injury in hHIF2a–/– and control mice fed the CDAA diet. hHIF2a–/– and wild-type littermates were fed the CDAA
diet for 12 or 24 weeks, and the following parameters were evaluated: parenchymal injury, as evaluated by measuring the serum levels
of ALT (A) or hepatic triglyceride content (B); body weight change (C); and plasma glucose concentration (D). Liver morphology in
mice exposed to the CDAA diet was evaluated by hematoxylin/eosin staining (magnification 310) (E). Values are means 6 SD and
refer to six to eight animals per group. Statistical differences were assessed by one-way analysis of variance test with Tukey’s correction
for multiple comparisons. Abbreviations: AUC, area under the curve; LM, littermate; TG, triglycerides.
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FIG. 4. Liver fibrosis “in vivo” in hHIF-2a–/– mice versus littermate mice fed the CDAA diet. Liver fibrosis was evaluated morpho-
logically in hHIF-2a–/– mice and wild-type littermates following 12 or 24 weeks on the CDAA or control CSAA diet by sirius red
staining (A) and IHC for a-SMA (D). Original magnification as indicated. ImageJ software analysis was performed for sirius red
staining to evaluate the amount of fibrosis (B). Analysis by quantitative real-time PCR of transcript levels of profibrogenic genes colla-
gen 1A1, a-SMA, and transforming growth factor b1 in the different experimental groups (C). Values are means 6 SD and refer to
six to eight animals per group. Statistical differences were assessed by one-way analysis of variance test with Tukey’s correction for
multiple comparisons. Abbreviations: ko, knockout; LM, littermate; TGF, transforming growth factor.
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lobular inflammation and the hepatic expression of
inflammatory markers TNFa, CD11b, and CCL2 were
also decreased in hHIF-2a–/– mice receiving the MCD
diet (Fig. 2D). On the same line, using CDAA-fed
mice we observed that the deletion of hepatocyte HIF-
2a (which was confirmed also by means of IHC in these
mice versus control littermates; see Supporting Fig. S3)
slowed down the time-dependent progression of
NAFLD (Fig. 3A,B,E) without affecting the gain in
body weight and the development of insulin resistance
(Fig. 3C,D). In this experimental model, hHIF-2a–/–
mice also showed less liver fibrosis at both 12 and 24
weeks, as evidenced by sirius red staining (Fig. 4A,B).
This paralleled a decrease in hepatic transcript for
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transforming growth factor b1, a-smooth muscle
actin (a-SMA), and collagen 1A1 (Fig. 4C), as well
as in the number of a-SMA-positive myofibroblasts
detected by IHC (Fig. 4D). Remarkably, the
protection from fibrosis was also evident in hHIF-
2a–/– mice receiving the MCD diet for up to 8 weeks
compared to control HIF-2a-sufficient littermates
(Supporting Fig. S4A-D).
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FIG. 5. Modulatory effect of HIF2a on HRGP. Western blotting analysis of HIF2a and HRGP levels in HepG2 cells exposed to
hypoxic conditions (A). Quantitative real-time PCR analysis of HRGP transcript in control HepG2 cells or HepG2 cells stably trans-
fected to overexpress HIF-2a (B). Data in graphs are expressed as means6 SEM. Quantitative PCR analysis of HRGP and cysteine-
X-cysteine receptor 4 transcripts in wild-type littermates or hHIF-2a–/– mice fed the control diet (CSAA) or the CDAA diet for 12
and 24 weeks (C). Hepatic mRNA was as fold increase over control values after normalization to the b-actin gene expression. Values
are means 6 SD and refer to six to eight animals per group. Statistical differences were assessed by one-way analysis of variance with
Tukey’s correction for multiple comparisons. Western blotting analysis of HRGP levels in liver of hHIF-2a–/– and littermate mice fed
the CDAA diet for 24 weeks (D). Histograms report densitometric analyses normalized for the relative glyceraldehyde 3-phosphate
dehydrogenase content. Localization of HRGP expression by IHC in the livers of wild-type littermates or hHIF-2a–/– CDAA-fed or
CSAA-fed animals. Original magnification as indicated. ImageJ software analysis was performed for quantification of HRGP staining
(E). Data are expressed as means6SD. Abbreviations: C, control; EV, empty vector; GAPDH, glyceraldehyde 3-phosphate dehydro-
genase; ko, knockout; LM, littermate.
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HEPATOCYTE-SPECIFIC
DELETION OF HIF-2a PREVENTS
THE PROGRESSION OF
EXPERIMENTAL NAFLD BY
AFFECTING HEPATOCYTE-
DEPENDENT RELEASE OF HRGP
To address the mechanisms by which hepatocyte
HIF-2a up-regulation promotes inflammatory
mechanisms in NAFLD, we focused our attention on
the role of HRGP, a hepatocyte-released mediator
(i.e., hepatokine) that has been recently shown to sup-
port liver macrophage activation in experimental and
clinical NAFLD/NASH.(32) To investigate the possi-
ble hypoxia-dependent and HIF-2a-dependent modu-
lation of HRGP, we employed HepG2 cells, which are
known to rapidly respond to hypoxia with HIF-2a sta-
bilization and the up-regulation of HIF-2a target
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genes.(28,33) Incubation of HepG2 cells under hypoxic
conditions, which is known to rapidly promote the
nuclear translocation of HIF-2a,(28) was associated
with an appreciable increase in HRGP synthesis (Fig.
5A). A very significant up-regulation of HRGP tran-
scription was also observed in HepG2 cells transfected
with an HIF-2a-containing vector but not with an
empty vector (Fig. 5B), confirming an HIF-2a-
dependent modulation of HRGP in liver cells.
According to the in vitro data, hepatic HRGP tran-
script levels increased in a time-dependent manner in
control mice fed the CDAA diet in parallel with the
up-regulation of the expression of another HIF-2a-
dependent gene such as cysteine-X-cysteine receptor 4
(Fig. 5C). Conversely, HRGP up-regulation associ-
ated with NAFLD evolution was almost completely
prevented at both the mRNA and protein levels in
hHIF-2a–/– mice (Fig. 5C,D). The relationships
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FIG. 6. Inflammatory markers in hHIF-2a–/– and control mice fed the CDAA diet. hHIF-2a–/– mice and wild-type littermates were
fed the CDAA or the CSAA diet for 12 or 24 weeks, and the detection of macrophages positive for F4/80 was evaluated by IHC
(original magnification as indicated). ImageJ software analysis was performed for quantification of F4/80 staining (A). Data are
expressed as means6 SD. Hepatic myeloid cells were isolated from livers of either hHIF-2a–/– mice or wild-type littermates fed the
CDAA diet analyzed by flow cytometry for Ly6C and IL expression in Cd11b/F4-80-positive liver macrophages. (B) Data are
expressed as means6 SD. Circulating IL-12 levels were determined by enzyme-linked immunosorbent assay (C). Values refer to six,
eight, or 10 animals per group; boxes indicate values within 25th and 75th percentiles, whereas horizontal bars represent the medians.
The extremities of the vertical bars (10th-90th percentile) comprise 80% of the values. Statistical differences were assessed by one-way
analysis of variance with Tukey’s correction for multiple comparisons. Abbreviation: LM, littermate.
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between HIF-2a and HRGP were further confirmed
by the evidence that HepG2 stably transfected to over-
express HIF-2a also overexpressed transcript levels of
other HIF-2a target genes such as cysteine-X-cysteine
receptor 4 and erythropoietin (Supporting Fig. S5A,B)
or, as previously reported, SerpinB3.(28) Moreover,
HRGP transcript and protein levels were down-
regulated in HepG2 cells exposed to hypoxic
conditions following efficient silencing for HIF-2a
(Supporting Fig. S5C,D). IHC performed on liver
from mice fed the CDAA diet confirmed that HRGP
was selectively expressed by hepatocytes of control
mice with steatohepatitis but not in those from hHIF-
2a–/– animals (Fig. 5E). Up-regulation of HIF-2a and
HRPG was unrelated to choline deficiency and was
also observed in mice with NAFLD induced by
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FIG. 7. HRGP expression in human livers with NASH. HRGP detection by IHC in liver specimens from NASH patients (n 5 27)
with different degrees of liver fibrosis (F0-F4, NAFLD activity score 2-6). “Control liver” refers to surgical resections for hepatic
metastasis of colon carcinoma. Original magnification as indicated. ImageJ software analysis was performed for quantification of
HRGP staining (A). Data are expressed as means6SD. HRGP expression was semiquantitatively scored by a pathologist. P values
were calculated with Mann-Whitney’s U test (B). Relationship between HRGP and HIF2a mRNA in human NASH patients (F0-
F4, NAFLD activity score 2-6) (C). Values represent the relative mRNA content. Correlation analysis was performed with Spearman’s
r test. Abbreviations: CTR, control; NAS, NAFLD activity score.
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administration in the drinking water of a high-fat/fruc-
tose diet (Supporting Fig. S6A-D). Hepatocyte-
derived HRGP has been recently shown to promote
liver inflammation by stimulating M1 polarization of
hepatic macrophages.(32) In our hands, the impaired
production of HRPG in mice receiving the CDAA
diet decreased the liver infiltration by F4/80-positive
macrophages as evidenced by both IHC (Fig. 6A) and
flow cytometry (Supporting Fig. S7A). Furthermore,
the fraction of inflammatory Ly6Chigh hepatic macro-
phages and their capacity to produce IL-12 were
significantly lower in hHIF-2a–/– mice compared to
control littermates (Fig. 6B). Consistently the hepatic
expression of M1 cytokines/chemokines TNFa,
IL-12p40, CCL2, and C-X-C-motif chemokine
ligand 10 (Supporting Fig. S7B); and the serum levels
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of IL-12 were also significantly reduced in hHIF-2a–/–
mice receiving the CDAA diet (Fig. 6C), indicating a
possible role of HRGP in the mechanisms by which the
stimulation of HIF-2a in parenchymal cells supports
proinflammatory responses of hepatic macrophages.
Finally, to further support the possible relevance of
the relationships between HIF-2a and HRGP in the
human disease, we analyzed for HIF-2a and HRGP
immune-staining serial sections (4 lm thick) in our
cohorts of NAFLD patients. Figure 7A shows that
HRGP positivity was very low in sections from control
livers. Conversely, in agreement with previous data,(32)
HPRG immune-staining was evident and increased in
liver samples from NAFLD patients irrespective of the
disease evolution (Fig. 7B,C) and colocalized with that
of HIF-2a (Fig. 7A). Furthermore, we found a signifi-
cant positive correlation between HIF-2a and HRGP
mRNA levels in those patients of this cohort (n 5 19)
for whom frozen liver specimens were available
(Fig. 7D).
Discussion
As mentioned in the introduction, hypoxia and
HIFs have been proposed to play a role in the progres-
sion of CLD.(8-11) However, data concerning their role
in the evolution of NAFLD are quite limited,(10) and,
more specifically, the contribution of HIF-2a has never
been investigated in detail. In the present study we
provide evidence that hepatocyte HIF-2a is up-
regulated in either human or experimental NAFLD
and propose a mechanism by which HIF-2a activation
in the liver parenchyma can contribute to the disease
progression.
We report that HIF-2a is specifically overexpressed
in hepatocytes during the development of human
NAFLD. In the majority of the liver biopsies from
NAFLD patients, nuclear localization of HIF-2a is
also evident, indicating that, by forming a heterodimer
with either HIF-1b or HIF-2b, HIF-2a can act as a
transcription factor. Interestingly, HIF-2a activation is
evident already in the early stage of the disease (F0-
F1), and it is maintained up to more advanced (F3-F4)
conditions of fibrosis/cirrhosis. Similar findings have
been detected in murine models of NAFLD. In this
setting, both HIF-2a and HIF-1a transcripts were up-
regulated in mice with steatohepatitis, but only those
of HIF-2a paralleled the disease progression. Alto-
gether, these data suggest that HIF-dependent
responses are an early event in NAFLD evolution and
can be involved in the disease progression. Hepatic
hypoxia likely represents the most obvious cause for
HIF-2a up-regulation in both human and experimen-
tal NAFLD. In fact, diffuse lobular staining with the
hypoxia-sensitive dye pimonidazole has been docu-
mented in mice with NAFLD.(21) Nevertheless, we
cannot exclude that hypoxia-independent mechanisms,
for instance, oxidative stress, might also contribute to
stimulate HIF-2a activity.(8-11)
The actual relevance of HIF-2a in NAFLD
progression has been mechanistically confirmed by
inducing NAFLD with the MCD or CDAA diet in
hHIF-2a–/– mice. We have observed that steatosis,
parenchymal injury, inflammatory response, and liver
fibrosis are appreciably attenuated in these animals
compared with control littermates. The decrease in
fatty liver detected in hHIF-2a–/– mice is consistent
with the observation that HIF-2a activation is per se
capable of promoting fatty liver by up-regulating genes
involved in fatty acid synthesis/uptake and lipid storage
and by down-regulating those involved in fatty acid
catabolism.(18,19) Accordingly, in the CDAA diet
model, transcript levels of sterol regulatory element
binding protein 1 and of fatty acid synthase were signifi-
cantly reduced in hHIF-2a–/– mice versus related con-
trol littermates exposed to the same diet (Supporting
Fig. S8). Moreover, employing murine hepatocytes
(AML12 line), we found that exposure of these cells to
palmitic acid (i.e., a condition leading to lipid accumu-
lation and mimicking “in vitro” lipotoxicity) resulted in
a significant up-regulation of both HIF-2a and HRGP
protein levels (Supporting Fig. S9A) and of HRGP
transcript levels (Supporting Fig. S9B), suggesting that
lipotoxicity may represent an additional condition lead-
ing to HIF-2a and HRGP up-regulation.
Furthermore, in a previous study using mice fed a
high-fat diet, hepatocyte deletion of HIF-1a effectively
prevented NAFLD-associated liver fibrosis without
interfering with fat accumulation.(21) Interestingly, the
same work also showed that hepatocyte HIF-1a defi-
ciency moderately affected parenchymal damage and
did not influence the extent of lobular inflamma-
tion.(21) This indicates that beside the action on steato-
sis, the activation of HIF-2a in hepatocytes has a key
role in favoring NAFLD-associated cell injury and
inflammatory responses.
To investigate whether hepatocyte HIF-2a might
stimulate the production of mediators with proinflam-
matory action, we focused attention on the possible
role of HRGP, a multifunctional hepatocyte-derived
circulating protein(34) that has been recently shown to
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be involved in modulating proinflammatory activity of
macrophages in tumors as well during chronic liver
injury.(32,35) In particular, Bartneck et al.(32) have
reported that HRGP deletion leads to a significant
protection from liver injury and fibrosis in mice with
MCD-induced NASH by down-modulating the
recruitment of hepatic macrophages and their M1
polarization. In this setting, our data demonstrate an
interplay between HIF-2a and HRGP during
NAFLD evolution by showing that the lack of hepato-
cyte HIF-2a prevents HRGP up-regulation in mice
fed the CDAA diet. Furthermore, HRGP staining of
liver biopsies from NAFLD patients colocalizes with
that of HIF-2a, while in the same subjects a positive
linear correlation is evident between the HIF-2a and
HRGP transcripts. These findings are supported by in
vitro experiments employing HepG2 cells exposed to
hypoxia or overexpressing HIF-2a that confirm the
strict HIF-2a dependence of HRGP production.
In line with the view that HIF-2a deficiency can
reduce hepatic inflammation by preventing HRGP-
mediated support to M1 activation of liver macro-
phages, we have observed that the liver expression of
M1 markers TNF-a, IL-12, and C-X-C-motif che-
mokine ligand 10 is blunted in hHIF-2a–/– mice with
NAFLD. Moreover, flow cytometry reveals that the
prevalence of proinflammatory Ly6Chigh hepatic mac-
rophages and their capacity to produce IL-12 are low-
ered in hHIF-2a–/– mice fed the CDAA diet. The
HIF-2a influence on macrophage responses is of
potential general relevance because it is well known
that the polarization of hepatic macrophages is a cru-
cial determinant for the progression of CLDs.(36) In
particular, the macrophage M1 shift has been reported
to correlate with the severity of both alcoholic and
nonalcoholic liver disease.(37,38) Accordingly, M2
skewing is associated with a more favorable histology
and fewer hepatic lesions in patients with ethanol-
related CLD(37) as well as in HRGP–/– mice exposed
to chronic liver injury.(32)
The involvement of HRGP in mediating the effects
of HIF-2a activation during NAFLD progression
does not rule out the possible involvement of other
mediators. We previously reported that HIF-2a activa-
tion in human liver cancer cells up-regulates Serpin B3
and that this contributes to the development of fibrosis
during CLD by sustaining the most relevant profibro-
genic responses by activated stellate cells.(28,30) Unfor-
tunately, unlike in humans, SerpinB3 is virtually
undetectable in murine livers during CLD; thus, in the
present study we did not have the chance to evaluate
its contribution to NAFLD progression. However,
based on the association between circulating levels of
Serpin B3 and the risk of fibrosis in patients with
chronic hepatitis C,(39) a possible role of Serpin B3 in
the evolution of human NAFLD cannot be excluded.
In conclusion, our data indicate that hepatocyte
HIF-2a activation during the evolution of human and
murine NAFLD has a role in disease progression by
mediating the up-regulation of HRGP expression,
which in turn critically influences the severity of steato-
hepatitis and fibrogenesis. These findings point to
HIF-2a and HIF-2a-dependent genes as putative tar-
gets for future therapeutic strategies in NAFLD, a dis-
ease that, at present, has no validated therapy.
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